Literature DB >> 21409374

Acute and chronic histological changes of the small bowel secondary to C. jejuni infection in a rat model for post-infectious IBS.

Walter Morales1, Mark Pimentel, Laura Hwang, David Kunkel, Venkata Pokkunuri, Benjamin Basseri, Kimberly Low, Hanlin Wang, Jeffrey L Conklin, Christopher Chang.   

Abstract

BACKGROUND: Campylobacter jejuni has been implicated in the pathogenesis of post-infectious irritable bowel syndrome (PI-IBS) in humans, effects which may be because of cytolethal distending toxin (CDT). In this study, we characterized both acute and chronic-phase histological changes of the small bowel in rats exposed to wild-type C. jejuni 81-176, or a strain that does not produce CDT, by using a validated rat model of PI-IBS.
METHODS: Sprague-Dawley rats were given 1.0 × 10(8) CFU of either wild-type C. jejuni 81-176 (C+, PI/C+) or the CDT-negative strain (CDT-), or vehicle alone (Control). Acute-phase rats (C+, CDT-) were euthanized on days 2, 4, 8, 16, and 32. Chronic-phase rats (PI/C+, Control) were euthanized 3 months after clearing the initial infection. Segments of duodenum, jejunum, and ileum were resected and the contents plated for C. jejuni culture, and tissue sections were stained for histology.
RESULTS: We observed preferential infection of the ileum and jejunum by Campylobacter jejuni. Compared with controls, epithelial cell basal membrane ballooning, villous tip disruption, and reduced villous-to-crypt ratios were observed for both C+ and CDT- rats. Villous widening, the only result significantly different in C+ vs. CDT- rats, was greatest at day 4 (134.1 ± 21.12 μm vs. 109.9 ± 10.6 μm for CDT-, P < 0.01). Little or no cellular inflammatory changes were seen during acute C. jejuni infection. Three months after clearing the initial infection, no histological changes remained.
CONCLUSION: Significant histological changes, with the absence of inflammatory cells, are seen in the duodenum, jejunum, and ileum of rats during acute infection with C. jejuni. These changes occurred irrespective of the presence or absence of the CDT toxin.

Entities:  

Mesh:

Year:  2011        PMID: 21409374     DOI: 10.1007/s10620-011-1662-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  A MyD88-deficient mouse model reveals a role for Nramp1 in Campylobacter jejuni infection.

Authors:  Robert O Watson; Veronica Novik; Dirk Hofreuter; María Lara-Tejero; Jorge E Galán
Journal:  Infect Immun       Date:  2006-12-28       Impact factor: 3.441

2.  Persistent Campylobacter jejuni infections in patients infected with the human immunodeficiency virus (HIV).

Authors:  D M Perlman; N M Ampel; R B Schifman; D L Cohn; C M Patton; M L Aguirre; W L Wang; M J Blaser
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

3.  Campylobacter infection.

Authors:  D A Robinson
Journal:  R Soc Health J       Date:  1981-08

Review 4.  Cytolethal distending toxin: limited damage as a strategy to modulate cellular functions.

Authors:  María Lara-Tejero; Jorge E Galán
Journal:  Trends Microbiol       Date:  2002-03       Impact factor: 17.079

5.  Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns.

Authors:  C Pigrau; R Bartolome; B Almirante; A M Planes; J Gavalda; A Pahissa
Journal:  Clin Infect Dis       Date:  1997-12       Impact factor: 9.079

6.  A new heat-labile cytolethal distending toxin (CLDT) produced by Campylobacter spp.

Authors:  W M Johnson; H Lior
Journal:  Microb Pathog       Date:  1988-02       Impact factor: 3.738

7.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

8.  Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

9.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

10.  Campylobacter enteritis in 188 hospitalized patients.

Authors:  T Pitkänen; A Pönkä; T Pettersson; T U Kosunen
Journal:  Arch Intern Med       Date:  1983-02
View more
  10 in total

Review 1.  The Traveling Microbiome.

Authors:  Mark S Riddle; Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

Review 2.  Colonization properties of Campylobacter jejuni in chickens.

Authors:  C Pielsticker; G Glünder; S Rautenschlein
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-03-17

Review 3.  The Host Cellular Immune Response to Infection by Campylobacter Spp. and Its Role in Disease.

Authors:  Sean M Callahan; Carolina G Dolislager; Jeremiah G Johnson
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

4.  Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

Authors:  Mark Pimentel; Walter Morales; Ali Rezaie; Emily Marsh; Anthony Lembo; James Mirocha; Daniel A Leffler; Zachary Marsh; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Enoch Bortey; William Forbes; Allen Yu; Christopher Chang
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

5.  The Typhoid Toxin Promotes Host Survival and the Establishment of a Persistent Asymptomatic Infection.

Authors:  Lisa Del Bel Belluz; Riccardo Guidi; Ioannis S Pateras; Laura Levi; Boris Mihaljevic; Syed Fazle Rouf; Marie Wrande; Marco Candela; Silvia Turroni; Claudia Nastasi; Clarissa Consolandi; Clelia Peano; Toma Tebaldi; Gabriella Viero; Vassilis G Gorgoulis; Thorbjørn Krejsgaard; Mikael Rhen; Teresa Frisan
Journal:  PLoS Pathog       Date:  2016-04-07       Impact factor: 6.823

6.  Reaction of antibodies to Campylobacter jejuni and cytolethal distending toxin B with tissues and food antigens.

Authors:  Aristo Vojdani; Elroy Vojdani
Journal:  World J Gastroenterol       Date:  2019-03-07       Impact factor: 5.742

7.  Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.

Authors:  Maysaa El Sayed Zaki; Dina Elhammady; Mona Foda Salama; Mostafa Abdelsalam; Asmaa Osama Bakr Osman
Journal:  F1000Res       Date:  2021-04-19

8.  Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome.

Authors:  Venkata Pokkunuri; Mark Pimentel; Walter Morales; Sam-Ryong Jee; Joel Alpern; Stacy Weitsman; Zachary Marsh; Kimberly Low; Laura Hwang; Reza Khoshini; Gillian M Barlow; Hanlin Wang; Christopher Chang
Journal:  J Neurogastroenterol Motil       Date:  2012-10-09       Impact factor: 4.924

Review 9.  Animal models to study acute and chronic intestinal inflammation in mammals.

Authors:  Janelle A Jiminez; Trina C Uwiera; G Douglas Inglis; Richard R E Uwiera
Journal:  Gut Pathog       Date:  2015-11-10       Impact factor: 4.181

10.  Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome.

Authors:  Ya-Nan Cao; Li-Juan Feng; Yuan-Yuan Liu; Kui Jiang; Mao-Jun Zhang; Yi-Xin Gu; Bang-Mao Wang; Jia Gao; Ze-Lan Wang; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.